Celltrion, Pfizer Applaud US Infliximab Decision, Aim For ‘16 Launch
This article was originally published in PharmAsia News
Executive Summary
South Korea's Celltrion and its partner Pfizer have welcomed a US FDA advisory panel decision to embrace Remsima/Inflectra, their biosimilar version of Remicade, and South Korean analysts are predicting strong growth based on expectations the US government will encourage cost savings through the use of such products.